Melanoma Trial Shows Positive Personalized mRNA Vaccine

Moderna and Merck announced intismeran with Keytruda met the primary goals in a Phase 3 melanoma trial, extending recurrence-free survival and reducing distant metastasis in about 1,137 high-risk patients. The results are described as a landmark for mRNA oncology and the first successful late-stage demonstration of an individualized cancer vaccine. Analysts say the data could reshape the oncology market, but real-world uptake, label expansions, pricing, and full details will determine impact. Regulatory reviews are expected next year, with full results to be shared at upcoming medical forums. The news triggered stock gains for Moderna and a rally for Merck. This development reflects a shift toward therapies tailored to a patient’s tumor mutations and could transform treatment for high-risk melanoma and other cancers.